Literature DB >> 35208843

Immunomodulation Potential of Probiotics: A Novel Strategy for Improving Livestock Health, Immunity, and Productivity.

A K M Humayun Kober1,2,3, Muhammad Shahid Riaz Rajoka1,2, Hafiza Mahreen Mehwish1,2, Julio Villena4, Haruki Kitazawa1,2.   

Abstract

Over the past decade, the use of probiotics as feed supplements in animal production has increased considerably due to the ban on antibiotic growth promoters in livestock. This review provides an overview of the current situation, limitation, and prospects for probiotic formulations applied to livestock. Recently, the use of probiotics in livestock has been suggested to significantly improve their health, immunity, growth performance, nutritional digestibility, and intestinal microbial balance. Furthermore, it was reported that the use of probiotics in animals was helpful in equilibrating their beneficial microbial population and microbial turnover via stimulating the host immune response through specific secretions and competitive exclusion of potentially pathogenic bacteria in the digestive tract. Recently, there has been great interest in the understanding of probiotics targeted diet and its ability to compete with harmful microbes and acquire their niches. Therefore, the present review explores the most commonly used probiotic formulations in livestock feed and their effect on animal health. In summary, this article provides an in-depth knowledge about the formulation of probiotics as a step toward a better alternative to antibiotic healthy growth strategies.

Entities:  

Keywords:  antimicrobial; healthy growth strategy; immunoregulatory effects of probiotics; livestock; probiotics

Year:  2022        PMID: 35208843      PMCID: PMC8878146          DOI: 10.3390/microorganisms10020388

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


1. Introduction

Antimicrobial resistance represents a global health problem that contributes to tens of thousands of deaths per year. Furthermore, the global demand for meat and dairy consumption is increasing at a rapid and unprecedented rate [1]. To fulfill this demand, many countries are shifting to intensive livestock production systems that use antimicrobial (AM) drugs to keep animals healthy and increase their development and productivity [2,3]. For example, Van Boeckel et al. (2015) found that between 2010 and 2030, the global consumption of AM agent for livestock industry increased by 67%, while on the other hand, the increase in AM agent consumption in the BRICS countries (Brazil, Russia, India, China, South Africa) will be 67%. Furthermore, Denmark was the foremost nation to report authorized antimicrobial agent manufacturing/sales data in 1996, under the name of Danish Integrated Additive Manufacturing Resistance Monitoring and Research Program (DANMAP). In 2011, the European Medicines Agency Surveillance of Veterinary Consumption group (ESVAC) published the first report on veterinary AM sales in eight countries (Czech Republic, Denmark, Finland, France, Netherlands, Norway, Sweden, UK) since 2005. The latest 2017 report provides an overview of AM sales across all EU countries. Furthermore, North American countries and Canada began collecting sales data for AM resistance monitoring in 2008 for the Canadian Comprehensive Program (CIPARS), which reports AM resistance and AM use. In Asia, Japan was the first country to launch the Japan Veterinary AM Monitoring System (JVARM) to report AM agent use [4]. In addition, current global trends in the use of AM agents in livestock animal feeds were represented in Figure 1. Therefore, the establishment of AM-free feeding system by using probiotics has been required for secure and healthy livestock production. The most commonly used probiotics in livestock are the strains of lactic acid bacteria (LAB) and Bifidobacterium [5]. In addition, gastrointestinal tract (GI) infections in livestock are considered a major global problem, with a negative economic impact on livestock farmers [6]. In this regard, the likelihood of using feed supplements to attain a healthier animal, welfare, and yield by manipulating the gut microbiota has received considerable attention over the past 30 years. Antibiotics have been applied widely to prevent and treat GI infection in livestock; however, the random uses of antibiotics in livestock are responsible for the development of antibiotic resistance, which has a long-lasting effect on the human body, as well as the destruction of gut microflora [7,8,9]. Probiotics might be used as a potential alternative therapy to treat gastrointestinal tract disorders and to enhance the endogenous immune function of the host (Figure 1).
Figure 1

Role of probiotics in livestock healthy growth strategy. Global consumption of AM (AM) in livestock production was estimated in 2010 and is projected to rise by 67%, by 2030. Global increase (67%) in AM consumption is due to the growing number of animals raised for meat and milk production. Probiotics used as a safer alternative to conventional antibiotic drug therapy.

Numerous probiotics might be used to improve the performance of ruminant and pig (Table 1, Table 2 and Table 3) animals. Numerous studies have demonstrated that probiotics can exert an AM effect against pathogens and improve animal health, as well as productivity [10,11]. Earlier, our group established a porcine intestinal epithelial (PIE) cell line and demonstrated that PIE cells are a useful in vitro tool for the selection of immunomodulatory LAB (immunobiotic LAB). Furthermore, our group has demonstrated that the in vitro and in vivo immunobiotic LAB is a good alternative to improve resistance against GI pathogens in the porcine host. Additionally, our laboratory has shown that the probiotic Lactobacillus with immunoregulatory functions can beneficially modulate the immune response in the gut through controlling the functions of PIE cells (Table 2 and Table 3) [10,11,12,13,14,15]. This contrasts with previous studies that recommend the modulation of gut microbiota and piglet immunity via appropriate probiotic strains, which will lead to better growth performance. Therefore, it is necessary to establish a non-toxic feeding system and a food safety system to ensure the safe and healthy production of animal husbandry. A recent study suggested that the probiotic-supplemented diet significantly improved the health status, growth performance, and intestinal morphology in pigs [16]. Similarly, it was suggested that the multi-species probiotic diet has excellent potential to endorse the growth performance and healthy status of pigs via modulation of gut microbiota [17].
Table 1

Summary of current pig trials (in vivo) measuring the effects of probiotics on health and productivity.

GenusSpecies/StrainsAge GroupProbiotic Effects in Respect toRef.
Weight Gain/Feed IntakeFeed Efficiency HealthImmunityOthers
Bacillus/Clostridium B. subtilis and C. butyricumGrowing-finishing pigs (GFP)-↑ Meat qua[18]
Lactobacillus/Enterococcus L. plantarum ATCC 4336, L. fermentum DSM 20016 and E. faecium ATCC 19434Weaned piglets (WP)---[19]
Bacillus/Saccharomyces B. subtilis and S. boulardiGFP -E. coli[20]
Lactobacillus L.plantarum ZJ316GFP-↑ Meat qua[21]
Bifidobacterium B. longum (AH1206)Neonatal piglets↑ Mucosal immune[22]
Lactobacillus L. fermentum Suckling/nursery piglets↓ Diarrhea[23]
Lactobacillus L. reuteri, B. subtillis and B. licheniformisWP-↓ Salmonella and E. coli[24]
Lactobacillus L.jensenii TL2937 (LjTL2937)GFP↑ Meat qua[11]
Bacillus B. toyonensis WP-↓ Enteric pathogens[25]
Bacillus/Clostridium B. coagulans, B.licheniformis, B. subtilis and C. butyricumWP↓ Fecal noxious gas emission[26]
Bifidobacterium B. longum WP↓ Intestinal colonization by pathogens [27]
Lactobacillus/Bifidobacterium L. spp., B. spp.GFP-↓ Post-weaning mortality[28]
Lactobacillus L. salivarius FFIG71 L. salivarius FFIG131 GFP---[29]
Bacillus B. subtilis PB6 WP↓ Fecal ammonia and diarrhea[30]
Lactiplantibacillus L. plantarum N14 GFP-↑ Meat qua[31]
Lactobacillus delbrueckii subsp. Delbrueckii TUA4408LWP↑ Meat qua[32]
Lactobacillus L. reuteri 1 (LR1) GFP--↑ Meat qua[33]
Lactobacillus L. plantarum BG0001 WP--↓ Fecal E. coli[34]

Abbreviations: ↑, increased; ↓, decreased; ↔, no significant difference between groups; -, not studied; qua, quality.

Table 2

Summary of current ruminant trials (in vivo) measuring the effects of probiotics on health and production.

GenusSpecies/StrainsSourceProbiotic Effects in Respect toRef.
Weight Gain/Feed IntakeFeed EfficiencyHealthImmunityOthers
-Multi-species probiotic Cattle -[35]
Enterococcus E. faecium M74 Calf--[36]
Bacillus/Saccharomyces B. cereus S. boulardii Sheep [37]
Kluyveromyces/Saccharomyces K. marximanus NRRL3234, S. cerevisiae NCDC42, S. uvarum ATCC9080Sheep---[38]
- Multi-species probioticCalf--[35]
- Multi-species probioticCattle---[39]
Saccharomyces S. cerevisiae or combination of S. cerevisiae and L. sporogenesSheep----[40]
- Multi-species probiotic LABCalves -↓ Weaning time[39]
Lactobacillus L.animalis SB310, L.paracasei subsp. Paracasei SB137 and B.coagulans SB117Calves-Improved gut microbiota[41]
Faecalibacterium F. prausnitzii Calves--[42]
Lactobacillus L. plantarum Calves↓ Weaning stress[43]
Pediococcus P. pentosaceusSheep -↑ Digestibility[44]
Lactobacillus L. acidophilus, S. cerevisiae, E. faecium, A. oryza, and B. subtilisCattle---[45]
Lactobacillus L. acidophilus Buffalo calves--↓ Fecal coliform[46]
Lactobacillus L. murinus CRL1695, L. mucosae CRL1696, L. johnsonii CRL1693,L. salivarius CRL1702Calves--↓ Diarrhea and calf mortality[47]
Ruminococcus R. flavefaciens Sheep---[48]
Lactobacillus L. sporogenes Calves---[49]

Abbreviations: ↑, increased; ↓, decreased; ↔, no significant difference between groups; -, not assessed.

Table 3

Summary of current trials in cell line as livestock animal model (in vitro) measuring the immunoregulatory effects of probiotics.

GenusSpecies/StrainsSourceExpt. ModeTimeProbiotic Effects in Respect toRef.
Anti-InflammationPro-InflammationImmune-HealthOthers
Lactobacillus L. acidophilus (LA) or L. rhamnosus GG (LGG)Dairy productsIPEC-J224 h↓ RVs titers[50]
Lactobacillus L. casei MEP221106Korean foodPIE48 h↑ AV immune[51]
Bifidobacterium B. breve MCC-117Human gutPIE48 h↓ Intestinal inflammation[12]
Lactobacillus L. casei OLL2768Dairy productsBIE48 h↑ APP[52]
Lactobacillus L. delbrueckii YogurtCaco-2Overnight--E. coli infection[53]
Bifidobacterium B. longum BB536 and B. breve M-16VInfantPIE48 h↑ APP[10]
Lactobacillus L. jensenii TL2937Human fecesPIE48 h↑ APP[11,54]
Bifidobacterium B. thermophilum and B. infantis/B. brevisFeedPIE48 h-[14,55]
Lactobacillus L. rhamnosus CRL1506Goat milkPIE48 h↑ AV[56]
Lactobacillus/Bifidobacterium L. ruminis SPM0211, B. longum SPM1205 and SPM1206HumanCaco-2 ↑ AV immune[57]
Lactobacillus L. salivarius FFIG53Pig intestinePIE48 h↑ APP[29]
Lactobacillus L. plantarum N14 and L. delbrueckii TUA4408LFermented picklePIE48 h-[58]
Bifidobacterium B.infantis MCC12 or B. breve MCC1274-BIE 48 h↓ RVs titers[15]
Lactobacillus L. delbrueckii OLL1073R-1YogurtPIE ↑ AV[59]
Bifidobacterium B. longum BB536 and B. breve M-16VHuman fecesPIE120 h-[60]
Lactobacillus L. plantarum CRL1506Goat milkPIE72 h-[61]
Lactobacillus Lactobacillus spp.ManureCaco-2 cells7–10 D---↓ Infections[62]

Abbreviations: ↑, increased; ↓, decreased; -, not assessed/provided; APP, anti-pathogenic potential; AV, antiviral; RVs, rotavirus.

Therefore, this review brings forward a summary of recent scientific literature, as well as its implications in terms of animal health and productivity of the main species of farm animals, such as pigs, cattle, goats, and sheep. This review also explores the mechanism of actions of immunomodulation by probiotic LAB in intestinal epithelial cells (IECs) in in vitro animal model.

2. Global Trends of Antimicrobial Uses in Livestock

The growing global demand for animal protein consumption is putting increasing pressure on bacteria to develop AM resistance. It was recently reported that the average annual global consumption per kilogram of animal AM agents utilized was within the range of 45 mg and 172 mg in cattle and swine, respectively [63]. Additionally, it has been estimated that the global AM consumption will increase by 67% (from 63,151 tons to 105,596 tons) in between 2010 and 2030, respectively (Figure 1). In between 2010 and 2030, the rapidly increasing trends for consumption of livestock have put pressure on shifting the production practices in developing nations, where extensive agribusiness systems will be replaced by extensive agricultural procedures [4]. For BRICS countries, the AM consumption trends will increase by 99%, which is higher than the projected citizen income growth in these nations. In India, for example, the consumption proportion of AM agents (30 kg per square kilometer) is likely to upsurge to 312% by 2030. Strangely, almost 70% of AM agents, considered medically important for human health by the FDA, were used in livestock in US, ultimately threatening human health and animal welfare [64]. Hence, many countries, such as the EU and Japan, have banned the use of AM agents as growth promoters. In addition, other countries, including China and the US, are planning to ban the addition of antibiotics to animal feed, and research will focus on growth promoters that do not affect human health [65]. A potential alternative solution to these problems is the addition of naturally derived dietary additives, such as probiotics, that have enhancing effects on livestock health and productivity (Table 1, Table 2 and Table 3). Recent research with probiotic LAB in livestock suggested that the LAB might be used as an alternative strategy to antibiotic growth promoters [11,18,32,59,60,61,62].

3. Application of Probiotics in In Vivo Studies for Pig Production

The microorganisms most commonly used as probiotics in pigs are presented in Table 1 and Table 2. The genus Lactobacillus might be considered one of the most prominent components of the host gut. Furthermore, to date, no such report on safety precautions linked to the use of Lactobacillus in swine had been compiled. In growing-finishing pigs, the supplementation of probiotics has shown beneficial effects on the intake of feed alongside animal average weight. Furthermore, the addition of probiotics significantly reduced the activity of blood complement, while no alterations have been noted in antibody levels, macrophages, and leukocytes activities [18,19]. On the other hand, the probiotic treatment might be helpful in enhancing the growth performance, quality, and productivity in livestock [11,20,21] (Table 3). Oral supplementation of probiotics to neonates alters early mucosa-associated colonization patterns in preterm piglets and, hence, reducing the mucosal atrophy and gut dysfunction, including diarrhea, which is one of the most serious gastrointestinal disorders disturbing preterm piglet neonates [22,23]. Furthermore, piglets are very susceptible to colonization of the gut by pathogenic microorganisms that cause growth retardation and diarrhea, starting from birth to post-weaning. Therefore, probiotics are suggested throughout this time period, and many studies have shown the effectiveness of such products [11]. It was suggested that the probiotic (L. reuteri, B. subtillis, and B. Licheniformis) supplementation of pigs after weaning enhances the performance of animals [24]. It was concluded that the probiotic supplementation was helpful in promoting a healthy intestine by improving the digestibility of the nutrient, reducing the fecal Salmonella, as well as E. coli contents, improving serum IgG level and probably also resistance to local infection. It was also reported that dietary supplementation with 0.1% (1.5 × 109 CFU/g) probiotics (B. coagulans, B. licheniformis, B. subtilis and C. butyricum) can improve growth performance, nutrient digestibility, blood profiles, and it can modulate the concentrations of Lactobacillus and E. coli and decrease fecal noxious gas emission in weaning pigs [66]. Kantas et al. (2015) reported that B. toyonensis improved health, as well as growth performance, and could protect against enteric pathogens in post-weaning piglets [25]. Multi-strain probiotics at 0.1% concentration might be used as an alternative to a growth-promoting strategy [26]. The probiotic LAB demonstrated excellent ability in decreasing the pathogen microbe intestinal colonization, as well as exciting local immune response and enhancing intestinal architecture [27,67] in piglets. On the other hand, the origin of probiotic strains, the dose of probiotics in different husbandry enhances, piglet age, and feed system might present contrasting outcomes with the same probiotic strains [68]. The results of Masumizu et al. (2019) suggest that L. salivarius FFIG131 and L. salivarius FFIG71 might be used as immunobiotic candidates for the development of new immunological feed in the future, which in turn enhance pay to enlightening immune health status in the porcine host [29]. B. subtilis PB6 feeding in weaning pigs increased feed efficiency and boosted immunity, along with reducing fecal ammonia and diarrhea [30]. The in vivo study by Islam et al. (2021) revealed that immunobiotic feeding resulted in significant positive health benefits when using rakkyo pickled juice fermented with L. plantarum N14 in pigs, thus increasing feed intake, efficiency, and carcass quality [31]. In addition, another study by Suda et al. (2021) suggested that the immunobiotic L. delbrueckii subsp. Delbrueckii TUA4408L okara feed significantly improved growth performance and meat quality in piglets [32]. Tian et al. (2021) investigated the influence of diet supplemented with L. reuteri 1 (LR1) or antibiotics (olaquindox and aureomycin) on the longissimus thoracis (LT) and concluded that the probiotic might enhance health condition and carcass quality of treated pigs as compared with the control group [33]. Diet supplementation with probiotics B. subtilis PB6 enhanced growth performance and immunity, alongside lowering ammonia emissions and diarrhea incidence [30]. Furthermore, the L. plantarum supplemented diet significantly enhanced growth performance, increased Lactobacillus fecal contents, and decreased E. coli counts in weaning pigs [34,69].

4. Application of Probiotics in In Vivo Studies for Ruminant Production

Probiotics for mature ruminant animals have primarily been chosen for targeting the rumen compartment, which would be the primary site of feed digestion [70]. A wide variety of strictly anaerobic bacteria, ciliate protozoa, anaerobic fungi, and archaea constitute the rumen microbial ecosystem, which is responsible for the breakdown and fermentation of 70–75% of food components [71,72]. Live yeast (Saccharomyces) formulations are by far the most commonly marketed products for ruminants [73,74]. Live yeasts have been proven to boost performance in dairy ruminants by improving their immunity [75]. Daily live yeast supplementation has also been shown to increase growth metrics (such as average daily weight gain, final weight, and food intake) in beef cattle [39,76]. Most of these effects have been linked to increasing overall culturable ruminal microbial population concentration, which leads to an enhanced activity of cellulolytic microorganism growth and increased fiber digestibility. Numerous previous studies indicated that probiotics in ruminants increased their performance [77,78], although some studies [79] found little or no changes. Furthermore, a recent study suggested that the symbiotic supplementation of a yeast-derived prebiotic and a B. subtilis significantly improved the health conditions and overall productivity during feedlot receiving period [80]. Additionally, it was demonstrated that the supplementation of probiotic yeast products improved the inflammatory response of cattle on these diets. In conclusion, overall benefits of Saccharomyces-based products on animal performance may be linked to improved cattle health and increased nutrient digestibility [81]. The probiotic was given to calves throughout their first month of life, and it enhanced their gut microbiota and growth performance, as well as some biometric parameters [41]. Hence, a high quantity of compound probiotics is suggested to progress rumen development and health status of Holstein calves [82]. It has been reported that probiotics containing Bacillus spores and nucleotides had no synergistic impact on calves’ development, welfare, or fecal bacteria; however, nucleotide supplementation reduces Lactobacillus feces levels [83]. Lambs that received probiotics in a post-weaning nourishment seemed to exhibit a better performance in terms of feed conversion ratio, growth performance, and nutrient digestibility [44]. Probiotics administered orally to dairy cows exhibited a systemic effect on gene expression, including genes involved in immunity and homeostasis [45]. Zhang et al. (2016) aimed to develop a diet enriched with L. plantarum and B. subtilis on Holstein calves, and the developed diet with L. plantarum improved growth performance, nutrient digestibility, and relieved weaning stress in calves [43]. In the case of buffalo calves, the supplementation with L. acidophilus increased body weight gain and feed efficiency [46,84]. The study suggests that the fermented milk containing LAB can be beneficial for young calves because of its positive impacts on health and growth [46,84]. Ruminococcus flavefaciens supplementation in feed increased production performance in sheep [48]. It has also been stated by Izadi et al. (2020) that the probiotic B. coagulans can be used as an improving factor to increase the quality of milk and of dairy foodstuffs [79,85].

5. Application of Probiotics Using Cell Lines as Livestock Animal Model (In Vitro Study)

The in vivo studies indicate that probiotics have been successfully used to improve growth performance, nutrient utilization, intestinal microbiota, and gut health of the main species of farm animals, such as pigs, cattle, goats and sheep (Table 1 and Table 2). Some functional feeds that contain probiotics are thought to improve intestinal immunity via inspiration of epithelial cells, as well as immunocompetent cells, through pattern recognition receptor and induction of cytokine in the GIT [86,87]. However, in the field of feed immunology, due to the unavailability of an adequate intestinal immunoassay system for farm animals, much about the underlying mechanisms of intestinal immunity in cattle remains unknown. As a result, developing a probiotics/immunobiotic evaluation system for probiotic supplementation of functional food to a farm animal model is critical. In these circumstances, our group developed porcine and bovine intestinal epitheliocyte (PIE and BIE) cell lines for the evaluation of probiotics/immunobiotics and immunogenicity using anti-inflammatory responses in PIE cell monolayers and a co-culture system with porcine Peyer’s patch immune cells as a Peyer’s patch culture model (Figure 2) [12,54,88,89,90].
Figure 2

The in vitro cellular research model for the assessment of immunomodulatory function of probiotics/immunobiotic in livestock.

Our work demonstrated that the intestinal epitheliocytes (PIE, BIE) are useful in vitro model systems for the assessment of relations between pathogens and porcine/bovine intestinal epithelial cells (IECs), for the selection of probiotic/immunobiotic microorganisms, and for the evaluation of underlying immunomodulatory mechanisms by probiotic LAB in IECs. Currently, our study and a few other in vitro studies focused on describing the “health-improving” activities of probiotics in farm animals, along with effects of immune-health promoting factor (Table 3). Treatment with L. acidophilus (LA) before rotavirus infection boosted PRV replication and IL-6 response to PRV infection, indicating that LA had an adjuvant effect. Following rotavirus infection, LGG therapy reduced the IL-6 response, indicating LGG’s anti-inflammatory properties in an IPEC-J2 cell line [50]. It was reported that L. casei MEP221106 significantly regulate the antiviral immune response in PIE cells via TLR3-mediated immune response [90]. Fujie et al. (2011) found that in a PIE cell line, B. breve MCC-117 has the ability to effectively control the inflammatory response produced by enterotoxigenic E. coli (ETEC). They also found that MCC-117 has excellent immunoregulatory activity, which was linked to strain ability to alter PIE and the interaction of immunological cells, resulting in the stimulation of regulatory T cells and prevention of ETEC-induced intestinal inflammation [12]. On the other hand, another study indicated that L. jensenii TL2937 significantly reduced pro-inflammatory cytokines and chemokine expression caused by ETEC, leading to prevention of inflammatory intestinal disorders [54]. Subsequently, Tomosada et al. (2013) showed that B. longum BB536 and B. breve M-16V strains reduced the expression of intereleukin-8, interleukin-6, and MCP-1 in PIE cells treated with heat-killed ETEC [10]. Similarly, Takanashi et al. (2013) showed that L. casei OLL2768 reduced inflammation in PIE cells by reducing the production of pro-inflammatory cytokines [52]. Furthermore, Abedi et al. (2013) demonstrated that L. delbrueckii exhibited excellent ability to inhibit E. coli infection in the gut by using Caco-2 cells [51]. Furthermore, L. jensenii TL2937 was reported to be able to stimulate the production of immunoregulatory factors, such as TGF- in EICs, and functionally modulate IECs to improve infection resistance and minimize non-protective inflammation [11]. Our study suggests that feed supplemented with B. thermophilum stimulates immune cells to exert immunoregulation, which indicates that this feed is likely to contribute to enhancing the health of piglets without using AM feed materials [55]. Kang et al. (2015) indicated that L. ruminis SPM0211, B. Longum SPM1205, and B. longum 1206 are proficient in preventing the in vitro and in vivo rotavirus replication. Additionally, it was suggested that the antiviral effects of probiotics are to be expected owing to their modulation of the immune response via regulation of type I IFNs [57]. Another study reported the ability of LAB to beneficially modulate the inflammatory response in PIE cells after being challenged with pathogenic bacteria ETEC and virus (poly (I:C)) and to modulate gut immunity in the porcine host [29]. Another recent study demonstrated that the L. delbruecki TUA4408L attenuate ETEC-induced inflammatory response in PIE via TLR-2 and ETEC-induced inflammatory cytokines were downregulated when PIE cells were pre-stimulated with TUA4408L [91]. A recent study by Kobayashi et al. (2017) proved that the B. infantis MCC12 or B. breve MCC1274 have the ability to lower RV titers in BIE cells and differentially control the innate immune response. Furthermore, it was indicated that the bacterial strains enhanced the antiviral factor production, such as IFN-β in RV-infected BIE cells. In addition, recently we reported that L. rhamnosus CRL1505 and L. plantarum CRL1506 are immunobiotic strains with the ability to enhance the fortification against viral intestinal infections, as demonstrated in PIE [15]. The PIE cell stimulation with poly (I:C) enhanced the production of IFN-α and IFN-β, chemokines, adhesion molecules, cytokines, and prostaglandin biosynthesis genes. CRL1505 and CRL1506 modulate the innate antiviral immune response in PIE cells and protect against viral infection and inflammatory damage in vivo [92]. Another recent study by Kanmani et al. (2018) demonstrated that L. delbrueckii OLL1073R-1 modulate the innate antiviral immune response in porcine intestinal epithelial cells [59]. A recent study by Iida et al. (2019) demonstrated that paraimmunobiotic Bifidobacteria (B. longum BB536 and B. breve M-16V) can be used as a substitute to enhance intestinal infection resistance or as therapeutic gears for decreasing the inflammation [60]. Mizuno et al. (2020) demonstrated that L. plantarum CRL1506 significantly enhanced the intestinal innate antiviral immune response [61]. Śliżewska et al. (2021) demonstrated that new Lactobacillus strains might be helpful in preventing intestinal infections by reducing the colonization of pathogenic bacteria [62]. As a result, the use of probiotic Lactobacillus strains may improve the safety and quality of animal-derived meat and food products. Therefore, previous studies suggest that the use of immunobiotics/probiotics has good potential for immunomodulation to prevent and improve different health disorders.

Limitation for the Use of Probiotics in In Vitro and In Vivo Research Model

It was shown that the in vitro studies have a variety of limitations that must be considered. Results obtained with different IECs, for example, must be taken with caution because not all cell lines have the same properties. It is also worth noting that culture circumstances can affect how some molecular traits are expressed. The molecular explanation of probiotic action in vivo will aid in the identification of authentic probiotics and in the selection of the most appropriate ones for disease prevention and/or treatment. Nevertheless, further studies are also required ① to determine whether the probiotics used in animal nutrition enter the human food chain and how they affect human health. ② Animal womb is in an aseptic state, but after birth, young animals are suddenly exposed to bacteria and virus. To prevent infection from pathogenic bacteria and viruses, young livestock develops immunogenic potential by acquiring not only immunoglobulin and cytokine from colostrum but also indigenous bacteria from the mother’s vagina and milk. Among them, if useful immunobiotics for raising animals without AM agents can be found, they will be safe for animals as well as humans. Therefore, more investigation will be required in order to find Lactobacillus in the form of immunobiotics, pursue the possibility of using them as AM substitutes, and try to construct immunobiotics library to establish the translocation route from mother to child, which will represent the translocation route of indigenous bacteria from mother to child. Further studies are also required ③ to elucidate the mechanisms of action of probiotic LAB strains—in particular those related to the immunoregulating ability of LAB strains through DCs activation via pattern recognition receptors (co-culture experiments with probiotics, DCs, and IECs as well as in 3D models); ④ to search for probiotics that can be used as drug alternatives in the prevention or treatment of various infectious diseases using in vitro and in vivo models; ⑤ to search for new techniques, such as genome editing and AI/IoT system, for the development of a healthy growth system with immunobiotics.

6. Application of Probiotics in Livestock Production

In recent decades, some studies were conducted to illustrate the new scope in the field of probiotics and to discover the potential probiotic microbes. According to Sun et al., (2021) multi-species probiotics consisting of L. acidophilus, L. casei, B. thermophilum, and E. faecium were successfully used to reduce the diarrhea caused by enterotoxigenic E. coli (ETEC) F18+ in newly weaned pig [93]. In addition, multi-species probiotics were helpful in enhancing growth performance through a reduction in intestinal inflammation, oxidative stress, and morphological damages. Sobrino et al. (2021) attempted to study AM substitutes in pig production. They used Ligilactobacillus salivarius strain retrieved from sow’s milk and fed it to pregnant sows and piglets. The results suggested that there was a notable reduction in the presence of antibiotic-resistant Lactobacillus, which became apparent in the treatment group [94]. In recent studies, it was suggested that Prevotella exerted positive consequences in pig production by enhancing growth performance and immune response [95,96,97,98]. The Lactobacillus, Escherichia, Shigella, and Bacteroides dominate the small intestine microbiota, while on the other hand, the Prevotella dominates the large intestinal microbiota during the newborn stage. Furthermore, the Prevotella dominates the pig’s small and large intestines after weaning [99]. Additionally, it was reported that the non-diarrheic piglets were found to have a considerably higher abundance of intestinal Prevotella than diarrheic piglets. Prevotellacea UCG-003 was the key bacterium in the non-diarrheic microbiota of piglets, according to co-correlation network analysis [98]. Ngo et al. (2021) used a new probiotic (B. amyloliquefaciens H57) in high concentrate feed pellets that reduces volatile fatty acid production and prevents flavor in pellet feed. That facilitates higher feed intake in ruminant animals [28]. In recent studies on anaerobic fungi, it was demonstrated that it contributes essentially to ruminal fiber utilization by degrading plant cell walls in two ways, i.e., enzymatically and mechanically [100,101]. Remarkably, ongoing exploration showed the affinity of fungal CAZymes for stubborn fiber, which might clarify the specific use of anaerobic fungi when lower quality forages were fed to ruminants. Therefore, this can also be used as a potential probiotic in ruminant nutrition [102]. Studies on the utilization of B. subtilis as a spore-shaping probiotic bacterium in livestock nutrition have shown no unsafe impacts and have exhibited the viability of its utilization as a probiotic, mostly because of its demonstrated AM, mitigating cell reinforcement and exhibiting enzymatic, and immunomodulatory action [103]. A study by Cai et al. (2021) enumerated that S. cerevisiae and C. butyricum and their blend enhanced rumen conditions by expanding the pH and diminishing oxidation and upgraded rumen maturation capacities by expanding absorbability of supplements and further developing VFA production; from that point on, further enhancements in production growth of heat-stressed goats were observed [104]. The Debaryomyces hansenii is also gaining attraction as a new potential probiotic for both terrestrial and aquatic animals. The oral delivery of D. Hansenii has been linked to probiotic features, such as immunostimulatory effects, gut microbiota regulation, increased cell proliferation, differentiation, and improved digestive function. Its bioactive molecules have been identified and linked to its immunomodulatory effect, including cell wall components and polyamines [105]. Therefore, there are many potential probiotic microbes that are still to be discovered, which might play an evolutionary role in livestock production.

7. Modes of Action of Livestock Probiotics

There are numerous proposed modes of action of livestock probiotics [106,107,108,109,110,111,112,113,114]. However, the major mechanisms of action proposed for probiotics are considered in the following segments (summarized in Figure 3).
Figure 3

Proposed modes of action of livestock probiotics. Schematic diagram illustrating potential mechanisms, whereby oral administration of probiotics might promote beneficial effects by changing the composition of intestinal microbiota, altering intestinal barrier function, bile salts, and production of Th1 cytokines. Additionally, probiotics containing LAB may down-regulate the expression of pro-inflammatory cytokines and chemokines. Decrease in the translocation of bacteria may occur as a result of the ability of probiotics to tighten the mucosal barrier. Probiotics disallow colonization by pathogenic bacteria through competition for nutrients, immune system up-regulation, and production of antitoxins. These mechanisms include ① Competitive exclusion for binding sites, ② Adhesion to the GIT,③ Enhancement of the epithelial barrier, ④ Increase in digestion and absorption of nutrients, ⑤ Competing with pathogenic bacteria for nutrients in the gut, ⑥ Production of AM substances, ⑦ Alteration in gene expression in pathogenic microorganisms, ⑧ Bacterial antagonism, ⑨ Bioconversion and ⑩ Immunomodulation. Abbreviations: ↑, increased; ↓, decreased; Th1, Type 1 T helper; Th2, Type 2 T helper; IEC, intestinal epithelial cells; DC: dendritic cell.

① Modification of the microbial population of the GIT: Probiotics might boost the population of beneficial microbes, such as Lactobacillus and Bifidobacterium, which subsequently restrict the growth of harmful bacteria by creating inhibitory chemicals and by competing for binding sites [115,116]. ② Adhesion to the GIT wall to prevent colonization by pathogenic microorganisms: The majority of enteric pathogens might colonize the intestinal epithelium and cause disease as a result [117]. As a result, Lactobacillus can adhere to the gut epithelium and compete with pathogens for adhesion receptors, such as glycoconjugates [118]. The Lactobacillus and Bifidobacterium have hydrophobic surface layer proteins that assist the bacteria non-specifically by adhering to the animal cell surface [119]. ③ Enhancement of the Epithelial Barrier: The experimental studies in model animal have shown that probiotics P. acidilactici improve intestinal barrier function by reducing the permeability of the intestinal epithelium translocation of enterotoxigenic E. coli to mesenteric lymph nodes in post-weaning piglets as compared to the control group after ETEC challenge [120]. Our current findings suggest that the L. jensenii TL2937 reduce the intracellular Ca2+ flux in DSS-challenged PIE cells, increasing the tightness of the tight junction [121]. ④ Increase in digestion and absorption of nutrients: In this case, the spore-forming bacteria enhance the production of extracellular enzymes, which facilitate nutrient digestion [122,123]. ⑤ Competing with pathogenic bacteria for nutrients in the gut: Probiotic bacteria might compete with pathogenic bacteria for nutrients and absorption sites by rapidly utilizing energy sources, potentially shortening the log phase of bacterial development [116]. ⑥ Production of antimicrobial substances: Several probiotic bacteria, particularly those that produce lactic and acetic acids, have the ability to suppress harmful microorganisms [124,125]. ⑦ Alteration in gene expression in pathogenic microorganisms: Probiotics might influence pathogenic bacteria’s quorum sensing, hence altering their pathogenicity. Fermentation products from L. acidophilus La-5 significantly suppressed the extracellular production of a chemical signal (autoinducer-2) by human enterohaemorrhagic E. coli serotype O157:H7, leading to inhibition of the virulent gene (LEE—locus of enterocyte effacement) expression in vitro [126]. ⑧ Bacterial antagonism: Probiotic microorganisms, once established in the gut, may produce organic acids, hydrogen peroxide, lactoferrin, and bacteriocin, which may exhibit either bactericidal or bacteriostatic properties [127]. ⑨ Bactericidal activity/Bioconversion: Lactobacillus convert lactose to lactic acid, lowering the pH to a point where pathogenic bacteria cannot survive. Furthermore, living yeasts compete with lactic acid-producing bacteria to digest sugars obtained from starch breakdown, thereby stabilizing rumen pH and minimizing the danger of acidosis [128,129,130]. ⑩ Immunomodulation: Our study has shown that probiotic LAB with immunoregulatory functions can beneficially modulate the immune response in the gut by modulating the functions of PIE cells [12,54,56]. In addition, probiotic LAB have proven to be capable of acting as immune modulators by enhancing macrophage activity [54], increasing local antibody levels, inducing the production of anti-inflammation cytokines (interleukin (IL)- 10, interferon (IFN)-γ, β, IL-1β, TGF-β), reducing IL-4, IL-6, IL-8, MCP-1, and activating killer cells [11,32,54]. Immunomodulation properties appear to be strain dependent, which means that dissimilar probiotics might have parallel mechanisms of action, whereas a single strain may have multiple mechanisms of action. Quite a lot of probiotic strains, for example, have comparable impact on the microbial community of gastrointestinal tract, although the mechanisms of action of certain probiotics are mostly unknown. The exact mode of action of probiotics is not well understood in the majority of studies on their impact on performance. Therefore, the mechanisms must be explored on a case-by-case basis because closely interrelated probiotics appear to have diverse ways of action. Probiotic effects are a result of the interaction between the host and the probiotic microorganism. As a result, more research into the host–microbe interaction could shed light on the probiotic mode of action. Rapid improvements in molecular techniques and genome sequencing for microbial ecology research will substantially aid our understanding of probiotic mechanisms of action.

8. Conclusions

In the present review, we provided an overview of the effects of probiotics, including NGP on livestock in terms of nutrition, health, productivity, and the mechanisms of action of probiotics. Additional knowledge on the in vitro system of livestock animal model for the study of the mechanisms of immunomodulation by probiotic LAB in IECs is also illustrated. Several livestock probiotics have been found effective in improving animal weight gain, feed conversion, digestibility of nutrients, IgG, immune status, intestinal microflora and gut health (increased Lactobacilli with decreased E. coli counts), intestinal morphology, milk yield and quality, meat production and carcass quality, and reduction of the risk of pathogen colonization, stress, and diarrhea in both pig and ruminant livestock industries. Probiotics can be used as drug alternatives in growth promoters and in the prevention or treatment of various infectious diseases. Finally, in this review we also suggest that immunobiotics LAB can modulate immune responses in intestinal epithelial and immune cells from livestock, suggesting many potential probiotics could be discovered by new techniques, such as genome editing and AI/IoT system for contributions to promote healthy livestock without using AM feed materials, which ultimately will lead to drug-independent healthy and productive livestock, as well as food safety system for food animals.
  99 in total

1.  Characterization, the Antioxidant and Antimicrobial Activity of Exopolysaccharide Isolated from Poultry Origin Lactobacilli.

Authors:  Muhammad Shahid Riaz Rajoka; Hafiza Mahreen Mehwish; Hafiz Fakhar Hayat; Nazim Hussain; Sobia Sarwar; Humaira Aslam; Ahmad Nadeem; Junling Shi
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

2.  Porcine small intestinal epithelial cell line (IPEC-J2) of rotavirus infection as a new model for the study of innate immune responses to rotaviruses and probiotics.

Authors:  Fangning Liu; Guohua Li; Ke Wen; Tammy Bui; Dianjun Cao; Yanming Zhang; Lijuan Yuan
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

3.  Isolation and functional characterization of exopolysaccharide produced by Lactobacillus plantarum S123 isolated from traditional Chinese cheese.

Authors:  Muhammad Saleem; Samiullah Malik; Hafiza Mahreen Mehwish; Muhammad Waqas Ali; Nazim Hussain; Mohsin Khurshid; Muhammad Shahid Riaz Rajoka; Yougen Chen
Journal:  Arch Microbiol       Date:  2021-03-31       Impact factor: 2.552

4.  Lactobacillus delbrueckii TUA4408L and its extracellular polysaccharides attenuate enterotoxigenic Escherichia coli-induced inflammatory response in porcine intestinal epitheliocytes via Toll-like receptor-2 and 4.

Authors:  Satoshi Wachi; Paulraj Kanmani; Yohsuke Tomosada; Hisakazu Kobayashi; Toshihito Yuri; Shintaro Egusa; Tomoyuki Shimazu; Yoshihito Suda; Hisashi Aso; Makoto Sugawara; Tadao Saito; Takashi Mishima; Julio Villena; Haruki Kitazawa
Journal:  Mol Nutr Food Res       Date:  2014-08-05       Impact factor: 5.914

5.  Effect of yeast culture feed supply on growth, ruminal pH, and digestibility of fattening calves.

Authors:  Omar Maamouri; Mondher Ben Salem
Journal:  Food Sci Nutr       Date:  2021-03-22       Impact factor: 2.863

6.  Structure and Function of the Fecal Microbiota in Diarrheic Neonatal Piglets.

Authors:  Qiaoli Yang; Xiaoyu Huang; Shengguo Zhao; Wenyang Sun; Zunqiang Yan; Pengfei Wang; Shenggui Li; Wangzhou Huang; Shengwei Zhang; Lixia Liu; Shuangbao Gun
Journal:  Front Microbiol       Date:  2017-03-24       Impact factor: 5.640

7.  Paraimmunobiotic Bifidobacteria Modulate the Expression Patterns of Peptidoglycan Recognition Proteins in Porcine Intestinal Epitheliocytes and Antigen Presenting Cells.

Authors:  Hikaru Iida; Masanori Tohno; Md Aminul Islam; Nana Sato; Hisakazu Kobayashi; Leonardo Albarracin; Akm Humayun Kober; Wakako Ikeda-Ohtsubo; Yoshihito Suda; Hisashi Aso; Tomonori Nochi; Ayako Miyazaki; Hirohide Uenishi; Noriyuki Iwabuchi; Jin-Zhong Xiao; Julio Villena; Haruki Kitazawa
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

8.  Dietary inclusion of multispecies probiotics to reduce the severity of post-weaning diarrhea caused by Escherichia coli F18+ in pigs.

Authors:  Yawang Sun; Marcos E Duarte; Sung Woo Kim
Journal:  Anim Nutr       Date:  2021-03-10

9.  Immunobiotic Lactobacillus jensenii TL2937 Alleviates Dextran Sodium Sulfate-Induced Colitis by Differentially Modulating the Transcriptomic Response of Intestinal Epithelial Cells.

Authors:  Nana Sato; Valeria Garcia-Castillo; Mao Yuzawa; Md Aminul Islam; Leonardo Albarracin; Mikado Tomokiyo; Wakako Ikeda-Ohtsubo; Apolinaria Garcia-Cancino; Hideki Takahashi; Julio Villena; Haruki Kitazawa
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

10.  Proteome specialization of anaerobic fungi during ruminal degradation of recalcitrant plant fiber.

Authors:  Live H Hagen; Charles G Brooke; Claire A Shaw; Angela D Norbeck; Hailan Piao; Magnus Ø Arntzen; Heather M Olson; Alex Copeland; Nancy Isern; Anil Shukla; Simon Roux; Vincent Lombard; Bernard Henrissat; Michelle A O'Malley; Igor V Grigoriev; Susannah G Tringe; Roderick I Mackie; Ljiljana Pasa-Tolic; Phillip B Pope; Matthias Hess
Journal:  ISME J       Date:  2020-09-14       Impact factor: 10.302

View more
  2 in total

1.  Effect of Clostridium butyricum Supplementation on in vitro Rumen Fermentation and Microbiota With High Grain Substrate Varying With Media pH Levels.

Authors:  Peixin Jiao; Ziwei Wang; Xin Wang; Yanan Zuo; Yuqing Yang; Guanghui Hu; Changming Lu; Xiaolai Xie; Li Wang; Wenzhu Yang
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

2.  Administration of probiotic lactic acid bacteria to modulate fecal microbiome in feedlot cattle.

Authors:  Flavia Ivana Mansilla; Cecilia Aristimuño Ficoseco; María Hortencia Miranda; Edoardo Puglisi; María Elena Fatima Nader-Macías; Graciela Margarita Vignolo; Cecilia Alejandra Fontana
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.